|
2025-01-13 |
2025-01-10 |
S
Sale
|
Bressi Jerome Charles
See Remarks
Officer
|
5,980
-2.2%
1.55
USD 9,269
|
5,980
-2.2%
|
1.55
|
USD 9,269
|
|
|
2025-01-13 |
2025-01-10 |
S
Sale
|
TAHL CINDY
See Remarks
Officer
|
5,654
-1.7%
1.55
USD 8,764
|
5,654
-1.7%
|
1.55
|
USD 8,764
|
|
|
2025-01-13 |
2025-01-10 |
S
Sale
|
Valamehr Bahram
President and CEO
Executive Director
|
8,705
-2.4%
1.54
USD 13,406
|
8,705
-2.4%
|
1.54
|
USD 13,406
|
|
|
2024-12-26 |
2024-12-20 |
B
Purchase
|
Redmile Group, LLC
Non-Executive Director
Large shareholder
|
397,964
+3.2%
1.68
USD 668,580
|
397,964
+3.2%
|
1.68
|
USD 668,580
|
|
|
2024-12-26 |
2024-12-20 |
S
Sale
|
Redmile Group, LLC
Non-Executive Director
Large shareholder
|
341,633
-2.7%
1.68
USD 573,943
|
341,633
-2.7%
|
1.68
|
USD 573,943
|
|
|
2024-08-07 |
2024-08-06 |
PS
Planned sale
|
Xu Yuan
Non-Executive Director
|
633
-6.8%
4.23
USD 2,678
|
633
-6.8%
|
4.23
|
USD 2,678
|
|
|
2024-03-05 |
2024-03-04 |
PS
Planned sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
2,447
-2.4%
7.77
USD 19,013
|
2,447
-2.4%
|
7.77
|
USD 19,013
|
|
|
2024-01-30 |
2024-01-29 |
PS
Planned sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
1,849
-1.7%
5.00
USD 9,245
|
1,849
-1.7%
|
5.00
|
USD 9,245
|
|
|
2024-01-10 |
2024-01-09 |
S
Sale
|
TAHL CINDY
General Counsel and Secretary
Officer
|
10,874
-7.1%
4.37
USD 47,519
|
10,874
-7.1%
|
4.37
|
USD 47,519
|
|
|
2024-01-10 |
2024-01-09 |
S
Sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
11,271
-6.7%
4.38
USD 49,367
|
11,271
-6.7%
|
4.38
|
USD 49,367
|
|
|
2024-01-10 |
2024-01-09 |
S
Sale
|
Wolchko J Scott
President and CEO
Executive Director
|
14,391
-3.7%
4.37
USD 62,889
|
14,391
-3.7%
|
4.37
|
USD 62,889
|
|
|
2024-01-10 |
2024-01-09 |
S
Sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
7,028
-6.2%
4.37
USD 30,712
|
7,028
-6.2%
|
4.37
|
USD 30,712
|
|
|
2024-01-03 |
2024-01-02 |
PS
Planned sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
5,182
-4.4%
3.66
USD 18,966
|
5,182
-4.4%
|
3.66
|
USD 18,966
|
|
|
2023-12-28 |
2023-12-26 |
B
Purchase
|
Redmile Group, LLC
Non-Executive Director
Large shareholder
|
44,630
+0.3%
3.72
USD 166,024
|
44,630
+0.3%
|
3.72
|
USD 166,024
|
|
|
2023-12-19 |
2023-12-18 |
PS
Planned sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
1,585
-1.3%
3.50
USD 5,548
|
1,585
-1.3%
|
3.50
|
USD 5,548
|
|
|
2023-11-13 |
2023-11-09 |
PS
Planned sale
|
TAHL CINDY
General Counsel and Secretary
Officer
|
24,363
-13.7%
2.40
USD 58,471
|
24,363
-13.7%
|
2.40
|
USD 58,471
|
|
|
2023-08-21 |
2023-08-18 |
S
Sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
4,718
-3.8%
2.80
USD 13,210
|
4,718
-3.8%
|
2.80
|
USD 13,210
|
|
|
2023-08-07 |
2023-08-04 |
PS
Planned sale
|
Xu Yuan
Non-Executive Director
|
632
-6.4%
3.71
USD 2,345
|
632
-6.4%
|
3.71
|
USD 2,345
|
|
|
2023-07-06 |
2023-07-05 |
PS
Planned sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
5,182
-4.0%
4.83
USD 25,029
|
5,182
-4.0%
|
4.83
|
USD 25,029
|
|
|
2023-07-06 |
2023-07-05 |
S
Sale
|
Powl Brian T.
Chief Commercial Officer
Officer
|
3,854
-8.6%
4.87
USD 18,769
|
3,854
-8.6%
|
4.87
|
USD 18,769
|
|
|
2023-06-15 |
2023-06-14 |
PS
Planned sale
|
Xu Yuan
Non-Executive Director
|
3,460
-25.8%
5.58
USD 19,307
|
3,460
-25.8%
|
5.58
|
USD 19,307
|
|
|
2023-04-21 |
2023-04-21 |
B
Purchase
|
Redmile Group, LLC
Non-Executive Director
Large shareholder
|
256,639
+2.0%
6.18
USD 1,586,029
|
256,639
+2.0%
|
6.18
|
USD 1,586,029
|
|
|
2023-04-21 |
2023-04-20 |
B
Purchase
|
Redmile Group, LLC
Non-Executive Director
Large shareholder
|
20,000
+0.2%
5.99
USD 119,800
|
20,000
+0.2%
|
5.99
|
USD 119,800
|
|
|
2023-04-19 |
2023-04-18 |
S
Sale
|
Chu Yu-Waye
Chief Medical Officer
Officer
|
2,317
-1.6%
6.58
USD 15,246
|
2,317
-1.6%
|
6.58
|
USD 15,246
|
|
|
2023-04-19 |
2023-04-18 |
S
Sale
|
Chu Yu-Waye
Chief Medical Officer
Officer
|
215
-0.2%
6.52
USD 1,402
|
215
-0.2%
|
6.52
|
USD 1,402
|
|
|
2023-04-17 |
2023-04-14 |
B
Purchase
|
Redmile Group, LLC
Non-Executive Director
Large shareholder
|
25,700
+0.2%
6.00
USD 154,200
|
25,700
+0.2%
|
6.00
|
USD 154,200
|
|
|
2023-04-17 |
2023-04-14 |
S
Sale
|
Redmile Group, LLC
Non-Executive Director
Large shareholder
|
302,339
-2.3%
5.84
USD 1,765,660
|
302,339
-2.3%
|
5.84
|
USD 1,765,660
|
|
|
2023-01-13 |
2023-01-13 |
B
Purchase
|
MENDLEIN JOHN
Non-Executive Director
|
36,631
+14.9%
5.43
USD 198,906
|
36,631
+14.9%
|
5.43
|
USD 198,906
|
|
|
2023-01-13 |
2023-01-11 |
B
Purchase
|
MENDLEIN JOHN
Non-Executive Director
|
88,048
+55.7%
5.67
USD 499,232
|
88,048
+55.7%
|
5.67
|
USD 499,232
|
|
|
2023-01-11 |
2023-01-10 |
S
Sale
|
Wolchko J Scott
President and CEO
Executive Director
|
45,907
-10.6%
5.24
USD 240,553
|
45,907
-10.6%
|
5.24
|
USD 240,553
|
|
|
2023-01-11 |
2023-01-10 |
S
Sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
10,917
-6.1%
5.24
USD 57,205
|
10,917
-6.1%
|
5.24
|
USD 57,205
|
|
|
2023-01-11 |
2023-01-10 |
S
Sale
|
Chu Yu-Waye
Chief Medical Officer
Officer
|
7,825
-5.2%
5.24
USD 41,003
|
7,825
-5.2%
|
5.24
|
USD 41,003
|
|
|
2023-01-11 |
2023-01-10 |
S
Sale
|
Plavsic Mark
Chief Technical Officer
Officer
|
3,418
-2.7%
5.24
USD 17,910
|
3,418
-2.7%
|
5.24
|
USD 17,910
|
|
|
2023-01-11 |
2023-01-10 |
S
Sale
|
TAHL CINDY
General Counsel and Secretary
Officer
|
11,553
-6.1%
5.24
USD 60,538
|
11,553
-6.1%
|
5.24
|
USD 60,538
|
|
|
2023-01-11 |
2023-01-10 |
S
Sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
7,331
-5.4%
5.24
USD 38,414
|
7,331
-5.4%
|
5.24
|
USD 38,414
|
|
|
2022-08-19 |
2022-08-18 |
S
Sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
432
-0.3%
30.41
USD 13,137
|
432
-0.3%
|
30.41
|
USD 13,137
|
|
|
2022-08-19 |
2022-08-18 |
S
Sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
4,703
-3.3%
29.75
USD 139,914
|
4,703
-3.3%
|
29.75
|
USD 139,914
|
|
|
2022-07-25 |
2022-07-22 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
620
-0.1%
33.28
USD 20,634
|
620
-0.1%
|
33.28
|
USD 20,634
|
|
|
2022-07-25 |
2022-07-22 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
2,703
-0.6%
32.61
USD 88,145
|
2,703
-0.6%
|
32.61
|
USD 88,145
|
|
|
2022-07-25 |
2022-07-22 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
2,923
-0.7%
31.33
USD 91,578
|
2,923
-0.7%
|
31.33
|
USD 91,578
|
|
|
2022-07-25 |
2022-07-21 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
19,171
-4.3%
33.07
USD 633,985
|
19,171
-4.3%
|
33.07
|
USD 633,985
|
|
|
2022-07-25 |
2022-07-21 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
10,829
-2.3%
32.54
USD 352,376
|
10,829
-2.3%
|
32.54
|
USD 352,376
|
|
|
2022-07-08 |
2022-07-07 |
PS
Planned sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
17,158
-8.7%
30.23
USD 518,686
|
17,158
-8.7%
|
30.23
|
USD 518,686
|
|
|
2022-07-07 |
2022-07-06 |
PS
Planned sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
7,842
-4.2%
30.07
USD 235,809
|
7,842
-4.2%
|
30.07
|
USD 235,809
|
|
|
2022-07-06 |
2022-07-05 |
S
Sale
|
Plavsic Mark
Chief Technical Officer
Officer
|
3,719
-2.8%
24.61
USD 91,525
|
3,719
-2.8%
|
24.61
|
USD 91,525
|
|
|
2022-06-08 |
2022-06-07 |
S
Sale
|
Agarwal Shefali
Non-Executive Director
|
841
-31.4%
21.89
USD 18,409
|
841
-31.4%
|
21.89
|
USD 18,409
|
|
|
2022-06-06 |
2022-06-03 |
S
Sale
|
Agarwal Shefali
Non-Executive Director
|
807
-30.1%
22.80
USD 18,400
|
807
-30.1%
|
22.80
|
USD 18,400
|
|
|
2022-06-06 |
2022-06-03 |
S
Sale
|
HERSHBERG ROBERT
Non-Executive Director
|
672
-25.1%
22.75
USD 15,288
|
672
-25.1%
|
22.75
|
USD 15,288
|
|
|
2022-06-06 |
2022-06-03 |
S
Sale
|
Jooss Karin
Non-Executive Director
|
1,483
-55.3%
22.82
USD 33,842
|
1,483
-55.3%
|
22.82
|
USD 33,842
|
|
|
2022-06-06 |
2022-06-03 |
S
Sale
|
MENDLEIN JOHN
Non-Executive Director
|
1,364
-0.9%
22.79
USD 31,086
|
1,364
-0.9%
|
22.79
|
USD 31,086
|
|
|
2022-06-06 |
2022-06-03 |
S
Sale
|
COUGHLIN TIMOTHY
Non-Executive Director
|
1,439
-2.4%
22.81
USD 32,824
|
1,439
-2.4%
|
22.81
|
USD 32,824
|
|
|
2022-06-02 |
2022-06-01 |
PS
Planned sale
|
TAHL CINDY
General Counsel and Secretary
Officer
|
25,000
-11.7%
22.96
USD 574,000
|
25,000
-11.7%
|
22.96
|
USD 574,000
|
|
|
2022-04-25 |
2022-04-22 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
838
-0.2%
35.15
USD 29,456
|
838
-0.2%
|
35.15
|
USD 29,456
|
|
|
2022-04-25 |
2022-04-22 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
9,162
-2.1%
34.54
USD 316,455
|
9,162
-2.1%
|
34.54
|
USD 316,455
|
|
|
2022-04-25 |
2022-04-21 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
1,003
-0.2%
37.90
USD 38,014
|
1,003
-0.2%
|
37.90
|
USD 38,014
|
|
|
2022-04-25 |
2022-04-21 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
2,220
-0.5%
36.70
USD 81,474
|
2,220
-0.5%
|
36.70
|
USD 81,474
|
|
|
2022-04-25 |
2022-04-21 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
4,062
-0.9%
35.73
USD 145,135
|
4,062
-0.9%
|
35.73
|
USD 145,135
|
|
|
2022-04-25 |
2022-04-21 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
22,715
-4.9%
34.57
USD 785,258
|
22,715
-4.9%
|
34.57
|
USD 785,258
|
|
|
2022-04-21 |
2022-04-19 |
S
Sale
|
Chu Yu-Waye
Chief Medical Officer
Officer
|
4,062
-2.6%
35.37
USD 143,673
|
4,062
-2.6%
|
35.37
|
USD 143,673
|
|
|
2022-04-04 |
2022-04-01 |
PS
Planned sale
|
TAHL CINDY
General Counsel and Secretary
Officer
|
25,000
-11.7%
38.85
USD 971,250
|
25,000
-11.7%
|
38.85
|
USD 971,250
|
|
|
2022-03-15 |
2022-03-14 |
PS
Planned sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
100
-0.1%
34.04
USD 3,404
|
100
-0.1%
|
34.04
|
USD 3,404
|
|
|
2022-03-15 |
2022-03-14 |
PS
Planned sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
2,960
-1.6%
33.30
USD 98,568
|
2,960
-1.6%
|
33.30
|
USD 98,568
|
|
|
2022-03-15 |
2022-03-14 |
PS
Planned sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
2,195
-1.2%
32.49
USD 71,316
|
2,195
-1.2%
|
32.49
|
USD 71,316
|
|
|
2022-03-15 |
2022-03-14 |
PS
Planned sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
3,067
-1.6%
31.66
USD 97,101
|
3,067
-1.6%
|
31.66
|
USD 97,101
|
|
|
2022-03-15 |
2022-03-14 |
PS
Planned sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
16,678
-8.1%
30.36
USD 506,344
|
16,678
-8.1%
|
30.36
|
USD 506,344
|
|
|
2022-03-11 |
2022-03-10 |
PS
Planned sale
|
MENDLEIN JOHN
Non-Executive Director
|
12,069
-7.0%
35.48
USD 428,208
|
12,069
-7.0%
|
35.48
|
USD 428,208
|
|
|
2022-03-11 |
2022-03-10 |
PS
Planned sale
|
MENDLEIN JOHN
Non-Executive Director
|
19,493
-10.2%
34.73
USD 676,992
|
19,493
-10.2%
|
34.73
|
USD 676,992
|
|
|
2022-01-24 |
2022-01-21 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
10,000
-2.3%
38.02
USD 380,200
|
10,000
-2.3%
|
38.02
|
USD 380,200
|
|
|
2022-01-24 |
2022-01-20 |
PS
Planned sale
|
Wolchko J Scott
President and CEO
Executive Director
|
30,000
-6.5%
40.21
USD 1,206,300
|
30,000
-6.5%
|
40.21
|
USD 1,206,300
|
|
|
2022-01-13 |
2022-01-11 |
S
Sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
390
-0.4%
49.16
USD 19,172
|
390
-0.4%
|
49.16
|
USD 19,172
|
|
|
2022-01-13 |
2022-01-11 |
S
Sale
|
Dulac Edward J III
Chief Financial Officer
Officer
|
1,380
-1.2%
48.25
USD 66,585
|
1,380
-1.2%
|
48.25
|
USD 66,585
|
|
|
2022-01-13 |
2022-01-11 |
S
Sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
418
-0.3%
49.12
USD 20,532
|
418
-0.3%
|
49.12
|
USD 20,532
|
|
|
2022-01-13 |
2022-01-11 |
S
Sale
|
Valamehr Bahram
Chief R&D Officer
Officer
|
4,152
-2.7%
48.44
USD 201,123
|
4,152
-2.7%
|
48.44
|
USD 201,123
|
|
|
2022-01-13 |
2022-01-11 |
S
Sale
|
Wolchko J Scott
President and CEO
Executive Director
|
4,519
-1.0%
49.07
USD 221,747
|
4,519
-1.0%
|
49.07
|
USD 221,747
|
|
|
2022-01-13 |
2022-01-11 |
S
Sale
|
Wolchko J Scott
President and CEO
Executive Director
|
10,047
-2.3%
48.50
USD 487,280
|
10,047
-2.3%
|
48.50
|
USD 487,280
|
|
